Patents by Inventor Edgar G. Engleman

Edgar G. Engleman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10966962
    Abstract: The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: April 6, 2021
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Khoa Dinh Nguyen, Edgar G. Engleman
  • Publication number: 20210059985
    Abstract: The present invention is directed to a method for preventing and/or treating aging-related cognitive impairment in the central nervous system. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
    Type: Application
    Filed: April 9, 2020
    Publication date: March 4, 2021
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Khoa Dinh NGUYEN, Edgar G. ENGLEMAN
  • Publication number: 20200163941
    Abstract: The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 28, 2020
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Khoa Dinh NGUYEN, Edgar G ENGLEMAN
  • Patent number: 10653669
    Abstract: The present invention is directed to a method for preventing and/or treating aging-related cognitive impairment in the central nervous system. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 19, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Khoa Dinh Nguyen, Edgar G. Engleman
  • Patent number: 10583125
    Abstract: The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: March 10, 2020
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO
    Inventors: Khoa Dinh Nguyen, Edgar G. Engleman
  • Publication number: 20190365716
    Abstract: The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
    Type: Application
    Filed: March 11, 2019
    Publication date: December 5, 2019
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Khoa Dinh Nguyen, Edgar G. Engleman
  • Patent number: 10272070
    Abstract: The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: April 30, 2019
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO R UNIVERSITY
    Inventors: Khoa Dinh Nguyen, Edgar G. Engleman
  • Publication number: 20180353474
    Abstract: The present invention is directed to a method for preventing and/or treating aging-related cognitive impairment in the central nervous system. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 13, 2018
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Khoa Dinh NGUYEN, Edgar G. ENGLEMAN
  • Publication number: 20170304269
    Abstract: The present invention is directed to a method for treating a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS), Alzheimer disease, Parkinson's disease, Huntington's disease, frontotemporal degeneration, dementia with Lewy bodies, a motor neuron disease, or a demyelinating disease. The method comprises administering to a subject in need thereof a Ppargc1a activator 2-(4-tert-butylphenyl)-1H-benzimidazole, 2-[4-(1,1-dimethylethyl)phenyl]-1H-benzimidazole, in an effective amount. A preferred route of administration is oral administration.
    Type: Application
    Filed: October 14, 2015
    Publication date: October 26, 2017
    Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO R UNIVERSITY
    Inventors: Khoa Dinh NGUYEN, Edgar G. ENGLEMAN
  • Patent number: 9248120
    Abstract: An agent that increases local concentration of retinoic acid (RA) in the intestine through modifying enzymatic pathways involved in RA metabolism is administered in a dose effective to inhibit or reverse production of inflammatory mediators by intestinal dendritic cells and thereby reduce intestinal inflammation and tumor growth associated with intestinal inflammation.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: February 2, 2016
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: Hweixian Leong Penny, Edgar G. Engleman
  • Patent number: 9220744
    Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
    Type: Grant
    Filed: January 11, 2014
    Date of Patent: December 29, 2015
    Assignee: Lumen Therapeutics, LLC
    Inventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
  • Publication number: 20140342986
    Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
    Type: Application
    Filed: January 11, 2014
    Publication date: November 20, 2014
    Applicant: Lumen Therapeutics, LLC
    Inventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
  • Patent number: 8629115
    Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
    Type: Grant
    Filed: October 20, 2010
    Date of Patent: January 14, 2014
    Assignee: Lumen Therapeutics, LLC
    Inventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
  • Publication number: 20130131129
    Abstract: An agent that increases local concentration of retinoic acid (RA) in the intestine through modifying enzymatic pathways involved in RA metabolism is administered in a dose effective to inhibit or reverse production of inflammatory mediators by intestinal dendritic cells and thereby reduce intestinal inflammation and tumor growth associated with intestinal inflammation.
    Type: Application
    Filed: August 22, 2012
    Publication date: May 23, 2013
    Inventors: Hwei Xian Leong, Edgar G. Engleman
  • Publication number: 20110124584
    Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
    Type: Application
    Filed: October 20, 2010
    Publication date: May 26, 2011
    Inventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
  • Patent number: 7820626
    Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: October 26, 2010
    Assignee: Lumen Therapeutics, LLC
    Inventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
  • Publication number: 20100240873
    Abstract: The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4+ T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the ligand and the antibodies in treatment of diseases and conditions of the immune system. The invention also provides methods of monitoring activated CD4+ T-cells using the ligands or fragments thereof.
    Type: Application
    Filed: March 8, 2010
    Publication date: September 23, 2010
    Inventors: Wayne Godfrey, Edgar G. Engleman
  • Patent number: 7557087
    Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
    Type: Grant
    Filed: April 18, 2007
    Date of Patent: July 7, 2009
    Assignee: Lumen Therapeutics, LLC
    Inventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider
  • Publication number: 20090069535
    Abstract: The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4+ T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified extracellular domains of ligands. The invention also provides humanized and human antibodies to the ligand. The invention further provides methods of using the ligand and the antibodies in treatment of diseases and conditions of the immune system. The invention also provides methods of monitoring activated CD4+ T-cells using the ligands or fragments thereof.
    Type: Application
    Filed: October 23, 2008
    Publication date: March 12, 2009
    Inventors: WAYNE GODFREY, EDGAR G. ENGLEMAN
  • Publication number: 20090053283
    Abstract: This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers and arginine homopolymers for use in organ perfusate and preservation solutions.
    Type: Application
    Filed: October 24, 2008
    Publication date: February 26, 2009
    Inventors: Jonathan B. Rothbard, Paul L. McGrane, Edgar G. Engleman, C. Garrison Fathman, Erik Kreider